An Anti-Inflammatory Sterol Decreases Obesity-Related Inflammation-Induced Insulin Resistance and Metabolic Dysregulation
Table 5
HE3286-0401 Heteroscedasticitya Between HE3286 and Placebo Changes from Baseline Values in Laboratory Parameters.
Group
Day
Parameter
HE3286
HE3286 > Placebo
Placebo
Placebo > HE3286
W test P
F test P
W test P
F test P
Cohort 1
84
ΔInsulind
>0.1
>0.1
<0.0001
0.007
ΔC-peptide
>0.1
>0.1
<0.0001
0.0495
ΔFasting glucose
>0.1
>0.1
0.02
>0.1
ΔHOMA2 %B
>0.1
>0.1
<0.0001
>0.1
ΔHOMA2 IR
>0.1
>0.1
0.002
0.049
Δleptin
>0.1
>0.1
0.005
>0.1
Cohort 1 MCP-1 > 40b
84
ΔHbA1c
>0.1
>0.1
0.006
>0.1
ΔFasting glucose
>0.1
>0.1
0.02
>0.1
ΔHOMA2 %B
>0.1
>0.1
<0.0001
>0.1
Cohort 2
84
ΔnHbA1c
>0.1
>0.1
0.04
>0.1
ΔInsulin
>0.1
>0.1
>0.1
0.004
ΔFasting glucose
>0.1
>0.1
0.03
>0.1
ΔHOMA2 %B
>0.1
>0.1
>0.1
0.006
ΔMCP-1
>0.1
>0.1
0.005
>0.1
ΔTriglycerides
>0.1
>0.1
<0.0001
0.007
112
ΔnHbA1c
>0.1
>0.1
0.0007
>0.1
ΔInsulin
>0.1
>0.1
>0.1
0.008
ΔFructosamine
>0.1
>0.1
0.002
>0.1
ΔHOMA2 %B
>0.1
>0.1
<0.0001
0.01
Cohort 2 BMI > 31c
84
ΔHOMA2 %B
>0.1
>0.1
0.007
>0.1
ΔMCP-1
>0.1
>0.1
>0.1
0.009
ΔTriglycerides
>0.1
>0.1
>0.1
0.001
112
ΔInsulin
>0.1
>0.1
<0.0001
0.001
ΔC-peptide
>0.1
>0.1
<0.0001
>0.1
ΔHOMA2 %B
>0.1
>0.1
<0.0001
>0.1
ΔHOMA2 IR
>0.1
>0.1
<0.0001
>0.1
>0.1
>0.1
>0.1
>0.1
aHeteroscedasticity describes differences in variances between groups. bParticipants with baseline monocyte chemoattractant protein greater than the lowest tertile (40 pmol/L, see results). cParticipants with baseline body mass index greater than the median (31 kg/m2, see results). dAbbreviations: Δ: change in; HOMA2 %B: homeostatic model assessment of pancreatic beta cell function; HOMA2 IR: homeostatic model assessment of insulin resistance; HbA1c: hemoglobin A1c; nHbA1c: HbA1c normalized to 84 day average hemoglobin mass; MCP-1: monocyte chemoattractant protein-1.
